Shilpa Medicare Approves Unaudited Results for Quarter Ended September 30, 2025
Shilpa Medicare board approves unaudited financial results for quarter ended September 30, 2025. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹13,493.28 lakhs.
The approval of financial results and a bonus issue can have a moderate impact on the stock. The sale of stake in JV and related party transactions also contribute to a medium impact.
The announcement primarily contains financial results and board approvals, which are considered neutral events. While there are mentions of increased profits, there are also mentions of exceptional losses due to provisions for impairment, balancing the overall sentiment.
* Shilpa Medicare Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, on November 13, 2025. * Standalone revenue from operations for the quarter ended September 30, 2025, was ₹13,493.28 lakhs compared to ₹12,968.24 lakhs for the quarter ended September 30, 2024. * Standalone net profit for the quarter ended September 30, 2025, was ₹3,082.83 lakhs compared to ₹2,999.18 lakhs for the quarter ended September 30, 2024. * Consolidated revenue from operations for the quarter ended September 30, 2025, was ₹36,996.88 lakhs compared to ₹34,379.74 lakhs for the quarter ended September 30, 2024. * Consolidated net profit for the quarter ended September 30, 2025, was ₹4,406.67 lakhs compared to ₹1,793.76 lakhs for the quarter ended September 30, 2024. * The company has entered into Definitive Share Purchase Agreement and Shareholder's Agreement dated October 27, 2025 with Ash Ingredients Inc. & Varcatalyst LLP to sell 31% of its stake in Sravathi Advance Process Technologies Pvt Ltd (SAPL) at a consideration of ₹4,960.05 lakhs. * Pursuant to the approval by the shareholders at their Annual General Meeting held on September 23, 2025, the Company has allotted on 07.10.2025 -9,77,90,908 fully paid-up Bonus Equity Shares of the face value of ₹1 each in the ratio of 1:1.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.